longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Fibrobiologics

FBLG

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI
  • Weekly Recap | MOAT.US -0.89%, lighter-volume pullback

    Weekly Review·2 days ago, 07:40 AM
    MOAT0.00%
  • Weekly Recap | ARKG.US +13.35%, AI healthcare leads genomics theme

    Weekly Review·2 days ago, 07:15 AM
    ARKG0.00%
  • Weekly Recap | Twist Bioscience +31.26%, signs deal with Lilly TuneLab

    Weekly Review·2 days ago, 06:54 AM
    TWST0.00%
  • Weekly Recap | RXRX.US +19.69%, most brokers rate it buy

    Weekly Review·2 days ago, 06:40 AM
    RXRX0.00%
  • Weekly Recap | Novavax +7.32%, outperforming the S&P 500

    Weekly Review·2 days ago, 06:28 AM
    NVAX0.00%
  • Weekly Recap | Medicinova +83.43%, most brokers rate it buy

    Weekly Review·2 days ago, 06:26 AM
    MNOV0.00%
  • Weekly Recap | LABU.US +0.73%, biotech ends mixed

    Weekly Review·2 days ago, 06:14 AM
  • Weekly Recap | ARQT.US +6.26%, consensus target above spot

    Weekly Review·2 days ago, 05:34 AM
    ARQT0.00%
  • Weekly Recap | Alnylam Pharma -3.67%, consensus target above spot

    Weekly Review·2 days ago, 05:31 AM
    ALNY0.00%
  • Weekly Recap | Abbvie +2.66%, closing in on record highs

    Weekly Review·2 days ago, 05:30 AM
    ABBV0.00%
  • Weekly Recap | SPDR S&P Biotech +0.33%, mixed biotech tape

    Weekly Review·2 days ago, 04:23 AM
    XBI0.00%
  • Weekly Recap | Fibrobiologics +25.69%, patent-fueled rally settles at $1.81

    Weekly Review·Sep 5 at 06:46 AM
    FBLG0.00%